Elanco Animal Health Inc

Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Elanco Animal Health reports mixed 2022 results, eyes innovation growth

Elanco Animal Health's 2022 performance showed revenue decline but EPS growth, with a focus on innovation and portfolio strength for future growth.
The company aims to address challenges like competitive pressures and interest expenses while leveraging opportunities in product launches and margin improvement.
Financial projections include a net leverage ratio target for 2023, with plans for debt reduction and enhanced cash flow generation in the coming years.
Elanco's strategic focus on OTC parasiticides, innovation, and operational efficiency positions it well for sustained growth and market differentiation.

Elanco Animal Health reports Q1 growth and strategic outlook

Elanco Animal Health's Q1 2023 performance showcased revenue growth, strategic advancements, and improved cash flow generation, supported by successful ERP system integration benefits.
Despite challenges related to free cash flow, inventory discrepancies, and regulatory discussions, the company remains focused on optimizing working capital and enhancing financial metrics.
Opportunities lie in debt repayment, maintaining pricing benefits, upcoming product launches, and returning to growth in the second half of 2023, underpinned by global macro trends.
Elanco's strengths in market positioning, innovation progress, and strategic outlook for 2024 position the company for sustained growth and operational excellence in the animal health sector.

Elanco Animal Health surpasses Q2 targets, eyes global market growth

Elanco Animal Health exceeded Q2 targets, focusing on innovation and market expansion. While facing challenges in certain segments, the company is optimistic about future growth opportunities through differentiated products and global market strengths.

Elanco Animal Health excels in Q3, eyes sustained growth in 2024

Elanco Animal Health delivered a strong Q3 performance, emphasizing innovation and growth in international segments. While facing challenges in U.S. Pet Health and Farm Animal generics, the company is focused on driving sustainable growth through margin expansion and new product launches. Opportunities lie in upcoming blockbuster product launches and pricing strategies for 2024.

Elanco Animal Health reports growth in Q4 2023 earnings

Elanco Animal Health's Q4 2023 performance showed revenue growth driven by innovation and Farm Animal business strength.
Strategic restructuring aims to enhance efficiency and focus on pet health, while challenges include competitive pressures and margin headwinds.
Opportunities lie in continued growth, innovation, debt reduction, and commitment to new product sales targets.
Overall, Elanco remains confident in its position and ability to navigate market challenges.

Elanco Animal Health surpasses Q1 expectations, eyes revenue growth

Elanco Animal Health's Q1 2024 performance exceeded expectations, driven by strong Pet Health and Farm Animal segment growth, alongside improved cash flow and late-stage pipeline progress.
Despite challenges like product manufacturing issues and market queries, Elanco remains focused on innovation, market positioning, and executing its value agenda.
The company is poised for revenue growth, with positive outlooks for late-stage products and opportunities to capitalize on market demand and competitive strategies.
Elanco's strategic approach to product launches, market readiness, and portfolio expansion positions it well for future growth and market leadership.

Elanco Animal Health reports strong Q3 performance and growth outlook

Elanco Animal Health's Q3 performance reflects growth in key segments and products, with a focus on debt reduction and strategic investments.
The company faces challenges in competitive markets and supply chain transitions but is poised for growth through new product launches and market adoption.
Opportunities lie in expanding product reach, driving innovation sales, and navigating pricing trends to achieve mid-single-digit growth in 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NORWALK, Conn., Aug. 2, 2021 /PRNewswire/ -- TriRx Pharmaceutical Services, LLC, a leading international CDMO, announced today that it has finalized and closed on an agreement with Elanco Animal Health Incorporated (NYSE:ELAN) to acquire the ownership and operations of its manufacturing site in Shawnee, Kansas.

TriRx Completes Acquisition of Elanco Animal Health Facility in Shawnee, Kansas

The pet health company buys yet another business in an effort to fast-track growth and expand its offerings.

This Acquisition Could Open a Whole New Market to Elanco

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) will announce its second quarter 2021 financial results on Monday, August 9, 2021. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco

Elanco Confirms Date and Conference Call for Second Quarter 2021 Financial Results Announcement

We believe that the stock price of Elanco, a pharmaceuticals company focused on medicines for pets and livestock, has more room for growth from its current levels of $35. ELAN stock is up 2x from the levels of around $17 it was at on March 23, 2020, when broader markets made a bottom.

What's Next For Elanco Stock After Kindred Acquisition?

Kindred Biosciences

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kindred Biosciences, Inc. (NasdaqGS: KIN) to Elanco Animal Health Incorporated (NYSE: ELAN). Under the terms of the proposed transaction, shareholders of Kindred will receive only $9.25 for each share of Kindred that they own. KSF is seeking to determine whether this consideration and the process that led to i

KINDRED BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kindred Biosciences, Inc. - KIN

Elanco Animal Health Inc (NYSE: ELAN) said on Wednesday it will acquire Kindred Biosciences Inc (NASDAQ: KIN) for roughly $440 million (£312 million) to expand its footprint in the pet health industry. The acquisition will bring three potential dermatology blockbusters, which are currently in the development phase, under Elanco's umbrella.

Kindred Biosciences to merge with Elanco Animal Health

Elanco Animal Health said it struck a $440 million deal to acquire Kindred Biosciences, a move that will bolster its drug pipeline, particularly the fast-growing pet dermatology segment.

Elanco Strikes Deal to Better Compete With Rival Zoetis in Pet Dermatology

Elanco Animal Health Incorporated (NYSE: ELAN) has agreed to acquire Kindred Biosciences Inc (NASDAQ: KIN) for $9.25 per share, or approximately $440 million. The price represents a premium of 52% based on the 30-day average.

Kindred Biosciences Stock Jumps On $440M Elanco Animal Buyout Deal

Elanco Animal Health Inc. said Wednesday it has entered an agreement to acquire Kindred Biosciences Inc. for about $440 million, adding three potential dermatology blockbusters to its pipeline. Under the terms of the deal, Elanco will pay $9.l254 a share for each Kindred share owned, equal to a 52% premium based on the 30-day average closing price.

Elanco Animal Health to acquire Kindred Biosciences for about $440 million; Kindred shares soar 45% premarket

GREENFIELD, Ind. and SAN FRANCISCO, June 16, 2021 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN) today announced the parties have entered into a definitive agreement for Elanco to acquire KindredBio, a biopharmaceutical company focused on developing novel pet therapeutics based on validated human targets.

Elanco Announces Agreement to Acquire Kindred Biosciences

Hold Elanco Despite Litigation Risks

NORWALK, Conn., June 15, 2021 /PRNewswire/ -- TriRx Pharmaceutical Services Inc., a leading international CDMO, today announced an agreement to acquire two facilities from Elanco Animal Health Incorporated (NYSE: ELAN).

TriRx Enters Agreement for the Acquisition of Elanco Animal Health Facilities in Shawnee, Kansas and Speke, United Kingdom

AmerisourceBergen

Chewy

Covetrus Inc

Freshpet

General Mills

Heska

IDEXX Laboratories

Merck

Nestle SA

Proshares Pet Care ETF

Patterson Companies

PetIQ

J. M. Smucker

Unicharm Corp

Petco Health and Wellness

Zomedica

Zoetis

The physiological and psychological benefits that pets give us are meaningful. COVID has amplified our appreciation of this. Anticipating 6% annual growth until 2030 may be conservative, even across developed markets.

Overview Of Opportunities In Animal Companionship: A $200B Industry Growing At 6.1% Annually

DaVita

National Vision Hlds

Henry Schein

Phibro Animal Health

Here are some MedTech stocks with favorable PEG ratio, which are expected to provide gains in 2021.

5 Probable MedTech Winners Post-COVID on Discounted PEG

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today released its 2020 Environmental, Social and Governance (ESG) Summary, including disclosure on climate-related and workforce metrics. The summary, its first since becoming a standalone animal health company less than three years ago, provides an initial view of the company's ESG programs, policies, and metrics aligned with its sustainability approach. “Sustainability is at the heart of our vision of Food and

Elanco Releases Environmental, Social and Governance (ESG) Summary

Following the acquisition of Bayer Animal Health, Elanco Animal Health Incorporated (NYSE: ELAN) has agreed to sell its sites in Shawnee, Kansas, and Speke, the U.K., to TriRx Pharmaceuticals, a Connecticut-based contract manufacturer with approximately 600 employees. The financial terms of the deal were not disclosed.

Elanco To Exit Three Manufacturing Sites To Streamline Footprint

G-III Apparel Group

NVIDIA

Titan Machinery

Top Ranked Momentum Stocks to Buy for June 9th

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today announced the next step in its journey to build a global, independent animal health leader with actions to optimize its manufacturing footprint. Following the acquisition of Bayer Animal Health, Elanco fully evaluated how to best allocate its manufacturing efforts to ensure efficient, reliable, quality supply for customers. As a result, Elanco has entered into an agreement with Connecticut-based TriRx Pharma

Elanco Announces Exit of Three Manufacturing Sites, Streamlining Footprint

GREENFIELD, Ind.--(BUSINESS WIRE)--Today, Elanco Animal Health Incorporated (NYSE: ELAN) named Marcela A. Kirberger as general counsel and corporate secretary. She joins the Elanco Executive Committee at the company's Greenfield, Indiana-based headquarters on June 22. Kirberger will have responsibility for all of Elanco's legal functions. She joins the company with more than 20 years of corporate legal experience advising and leading companies through transformation to address evolving internal

Elanco Announces Addition of Marcela A. Kirberger as General Counsel and Corporate Secretary

ArcBest

Cornerstone Building Brands Inc

Oshkosh

Top Ranked Momentum Stocks to Buy for May 21st

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) launches ZoaShield™ in the United States, which offers poultry producers a proven and flexible zoalene solution that keeps coccidiosis under control in an easy, manageable way. A critical component of maintaining optimal bird health, especially in No Antibiotics Ever (NAE) flocks, is having a reliable, efficacious anticoccidial program. ZoaShield offers producers a flexible, proven active ingredient product that c

Elanco Launches Product for U.S. Poultry Producers, Providing a Flexible Option for Cocci Control

Elanco Animal Health Incorporated (ELAN) CEO Jeff Simmons on Q1 2021 Results - Earnings Call Transcript

Elanco Animal Health Inc (NYSE: ELAN) has reported Q1 EPS of $0.37 higher than $0.13 reported a year ago. It surpassed analysts' estimate of $0.23 and beat the company guidance of $0.20 - $0.25.

Elanco Shares Rise After Q1 Earnings Exceed Expectations, Raises FY21 Outlook

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 60.87% and 7.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Elanco Animal Health Incorporated (ELAN) Q1 Earnings and Revenues Top Estimates

GREENFIELD, Ind.--(BUSINESS WIRE)--Elanco Animal Health Incorporated (NYSE: ELAN) today reported strong financial results for the first quarter of 2021, provided guidance for the second quarter of 2021, and updated guidance for the full year 2021. The results reflect the inclusion of the Bayer Animal Health business Elanco acquired on August 1, 2020. "Elanco started the year with better than expected results, building on the strong momentum our business has shown since closing the Bayer Animal

News for Elanco Animal Health Inc Stock (ELAN)